Literature DB >> 6861378

IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice.

.   

Abstract

There is a consensus amongst clinical immunologists that an effort should be made to define, for non-specialists, criteria and indications for administering immunoglobulin (gammaglobulin, immune serum globulin [ISG]) to patients. In addition to the well established immunoglobulin preparations for intramuscular injection, preparations rendered suitable for intravenous administration have recently become available, opening new prospects for the use of this material. The present report has been prepared by members of the Clinical Immunology Committee of the International Union of Immunological Societies in collaboration with the World Health Organization. It aims to delineate current recommendations for the use and dosage of immunoglobulin in the prophylaxis of viral and bacterial infections and in replacement of antibodies in immunodeficient patients. It is a further aim of this report to point out clearly those situations where immunoglobulin is not deemed to be useful or is contraindicated. Inappropriate use of this valuable material results in excessive and unnecessary costs for health services, carries some risk and is wasteful. This report also summarizes current knowledge on adverse reactions to immunoglobulin injections and those qualities which would be most desirable, if not essential, for safe and useful immunoglobulin preparations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861378      PMCID: PMC1535861     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  8 in total

Review 1.  Intravenous immunoglobulin in immunodeficiency states: state of the art.

Authors:  Elias Toubi; Amos Etzioni
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  The clinical use of intravenous immunoglobulin in pediatrics.

Authors:  V Wahn
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

3.  Immunoglobulin A concentrations in commercial immune globulins.

Authors:  R Apfelzweig; D Piszkiewicz; J A Hooper
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

4.  Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments.

Authors:  F Ramisse; F X Deramoudt; M Szatanik; A Bianchi; P Binder; C Hannoun; J M Alonso
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

5.  Prophylactic effect of human immunoglobulin against pneumococcal post-splenectomy sepsis in the rat.

Authors:  K Offenbartl; P Christensen; P Gullstrand; K Prellner
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

6.  Hypogammaglobulinemia in children undergoing continuous ambulatory peritoneal dialysis.

Authors:  B A Fivush; B Case; M W May; H M Lederman
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

7.  Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).

Authors:  Alessandra Vultaggio; Chiara Azzari; Silvia Ricci; Baldassarre Martire; Valentina Palladino; Vera Gallo; Antonio Pecoraro; Claudio Pignata; Giuseppe Spadaro; Simona Graziani; Viviana Moschese; Antonino Trizzino; Giorgio Maria Boggia; Andrea Matucci
Journal:  J Clin Immunol       Date:  2018-06-28       Impact factor: 8.317

8.  Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G.

Authors:  Willem Jan R Fokkink; David Falck; Tom C M Santbergen; Ruth Huizinga; Manfred Wuhrer; Bart C Jacobs
Journal:  PLoS One       Date:  2015-10-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.